Phaseline

Companies › Organon and

Organon and: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 3, 1 Phase 2; Immunology; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tapinarof
Aryl hydrocarbon receptor agonist
AHRPhase 3Plaque Psoriasis; Atopic Dermatitis; Palmoplantar KeratodermaAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05172726TapinarofPhase 3Plaque PsoriasisImmunologyOct 2026
NCT07265479TapinarofPhase 3Atopic DermatitisImmunologyAug 2027
NCT06561321TapinarofPhase 2Palmoplantar KeratodermaImmunologyDec 2027

From the company's SEC filings

Cash of $1.5bn on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Complete response letters from FDA

Agreements filed with the SEC (item 1.01), last two years

Targets

AHR (1)

Companies with the same targets

Birch BioMed

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.